FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q46258281> ?p ?o ?g. }

• Q46258281 description "2013 nî lūn-bûn" @default.
• Q46258281 description "2013年の論文" @default.
• Q46258281 description "2013年学术文章" @default.
• Q46258281 description "2013年学术文章" @default.
• Q46258281 description "2013年学术文章" @default.
• Q46258281 description "2013年学术文章" @default.
• Q46258281 description "2013年学术文章" @default.
• Q46258281 description "2013年學術文章" @default.
• Q46258281 description "2013年學術文章" @default.
• Q46258281 description "2013年學術文章" @default.
• Q46258281 description "2013年學術文章" @default.
• Q46258281 description "2013年學術文章" @default.
• Q46258281 description "2013年學術文章" @default.
• Q46258281 description "2013년 논문" @default.
• Q46258281 description "article científic" @default.
• Q46258281 description "article scientific" @default.
• Q46258281 description "article scientifique (publié 2013)" @default.
• Q46258281 description "articol științific" @default.
• Q46258281 description "articolo scientifico" @default.
• Q46258281 description "artigo científico (publicado na 2013)" @default.
• Q46258281 description "artigo científico (publicado na 2013)" @default.
• Q46258281 description "artigo científico" @default.
• Q46258281 description "artikull shkencor" @default.
• Q46258281 description "artikulong pang-agham" @default.
• Q46258281 description "artykuł naukowy" @default.
• Q46258281 description "artículo científico publicado en 2013" @default.
• Q46258281 description "artículu científicu" @default.
• Q46258281 description "bilimsel makale" @default.
• Q46258281 description "bài báo khoa học" @default.
• Q46258281 description "mokslinis straipsnis" @default.
• Q46258281 description "naučni članak" @default.
• Q46258281 description "scienca artikolo" @default.
• Q46258281 description "scientific article" @default.
• Q46258281 description "teaduslik artikkel" @default.
• Q46258281 description "tieteellinen artikkeli" @default.
• Q46258281 description "tudományos cikk" @default.
• Q46258281 description "vedecký článok" @default.
• Q46258281 description "vetenskaplig artikel" @default.
• Q46258281 description "videnskabelig artikel (udgivet 2013)" @default.
• Q46258281 description "vitenskapelig artikkel" @default.
• Q46258281 description "vitskapeleg artikkel" @default.
• Q46258281 description "vědecký článek" @default.
• Q46258281 description "wetenschappelijk artikel" @default.
• Q46258281 description "wissenschaftlicher Artikel" @default.
• Q46258281 description "επιστημονικό άρθρο" @default.
• Q46258281 description "мақолаи илмӣ" @default.
• Q46258281 description "мақолаи илмӣ" @default.
• Q46258281 description "наукова стаття, опублікована в липні 2013" @default.
• Q46258281 description "научна статия" @default.
• Q46258281 description "научная статья" @default.
• Q46258281 description "научни чланак" @default.
• Q46258281 description "научни чланак" @default.
• Q46258281 description "գիտական հոդված" @default.
• Q46258281 description "מאמר מדעי" @default.
• Q46258281 description "سائنسی مضمون" @default.
• Q46258281 description "مقالة علمية" @default.
• Q46258281 description "مقالهٔ علمی" @default.
• Q46258281 description "২০১৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
• Q46258281 description "บทความทางวิทยาศาสตร์" @default.
• Q46258281 description "სამეცნიერო სტატია" @default.
• Q46258281 name "Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease." @default.
• Q46258281 name "Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease." @default.
• Q46258281 type Item @default.
• Q46258281 label "Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease." @default.
• Q46258281 label "Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease." @default.
• Q46258281 prefLabel "Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease." @default.
• Q46258281 prefLabel "Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease." @default.
• Q46258281 P1433 Q46258281-696832D9-A5BC-41A1-B7D6-1238C118DA4F @default.
• Q46258281 P1476 Q46258281-6589538F-48D5-4BEF-97F1-446EB52C1EF9 @default.
• Q46258281 P2093 Q46258281-41F215FD-0F6F-4D85-880F-04EBCA0C87C4 @default.
• Q46258281 P2093 Q46258281-4E86A011-F1D9-47D5-8C1A-3F265936CBCD @default.
• Q46258281 P2093 Q46258281-5D62B844-8BCB-4245-8CCA-058973D895A0 @default.
• Q46258281 P2093 Q46258281-80DC3A85-4F29-4688-9225-406CD1C911F1 @default.
• Q46258281 P2093 Q46258281-8D6D91AD-F4DD-45AE-A2AA-D67694886BDE @default.
• Q46258281 P2093 Q46258281-D9197151-9C47-4F43-BA77-121C021389F1 @default.
• Q46258281 P2093 Q46258281-E772DEDA-5B72-47F1-AA19-A5474A78306F @default.
• Q46258281 P2093 Q46258281-EB3230D3-CF52-455C-B62E-659C84DB01D9 @default.
• Q46258281 P2093 Q46258281-FB2FCA50-6D41-41CD-85A1-2F12B80692E3 @default.
• Q46258281 P2860 Q46258281-1395C9E8-CFB4-49E2-A3C7-D3056B6E7265 @default.
• Q46258281 P2860 Q46258281-277BB80F-2A2C-47E2-946B-A94D5B68EF7B @default.
• Q46258281 P2860 Q46258281-38328319-62BD-451C-BE0B-7239F856C9F5 @default.
• Q46258281 P2860 Q46258281-45FE9E3F-9643-4095-BCBB-EF4EA2352636 @default.
• Q46258281 P2860 Q46258281-498B07F7-203B-40D3-884F-17F89D40E3AE @default.
• Q46258281 P2860 Q46258281-63468F5F-5DA4-4710-8065-3FAE116762EE @default.
• Q46258281 P2860 Q46258281-634919BD-9DC0-4FED-A9C1-C37D5C2C687C @default.
• Q46258281 P2860 Q46258281-B8F3CBA3-68A3-4CAF-831C-62F228B4D9C3 @default.
• Q46258281 P2860 Q46258281-D6398E53-1F5F-4620-A21F-99CE29967AFF @default.
• Q46258281 P2860 Q46258281-D81FC8B0-85F7-467A-B9E2-CE1A7FC6473B @default.
• Q46258281 P304 Q46258281-3048D648-3CBD-47BC-BD19-922CD300F8A5 @default.
• Q46258281 P31 Q46258281-A31A5909-98CD-4451-9515-2E63971FF297 @default.
• Q46258281 P356 Q46258281-C8467AF6-3518-475E-8562-B5356301E785 @default.
• Q46258281 P433 Q46258281-F57EE10B-F071-4824-BB73-BFC15050E61C @default.
• Q46258281 P478 Q46258281-97CC2C29-A274-4EBB-BBF3-FE22EF728037 @default.
• Q46258281 P50 Q46258281-19A18E0C-1433-4EB8-B1D9-4C1C402AE7E8 @default.
• Q46258281 P577 Q46258281-CBE0E4E0-8FB2-4120-8A28-B4D7DF60DDFE @default.
• Q46258281 P698 Q46258281-71CFB7C8-4749-4D44-9A85-82078711E6E3 @default.
• Q46258281 P921 Q46258281-37168489-F8C1-4E49-9511-F2C95DAC42AE @default.
• Q46258281 P921 Q46258281-6533AF8F-245A-4AB2-BE99-65877C79EE34 @default.
• Q46258281 P921 Q46258281-A199CF92-6907-43AC-B56C-A00A799B8935 @default.
• Q46258281 P921 Q46258281-E80BC08F-8F11-4F7B-AB0D-7F0AAF6B9AA4 @default.

• next